Atezolizumab is used for the treatment of metastatic urothelial carcinoma that has progressed during or following platinum-containing chemotherapy; it is also approved for first-line treatment of unresectable locally advanced or metastatic PD-L1-positive triple-negative breast cancer (TNBC) in combination with chemotherapy (nab-paclitaxel). Additionally, it is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) that has progressed during or after platinum-based chemotherapy.